Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).
about
Guanylate cyclase stimulators for pulmonary hypertensionTreatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguatQuality of life in patients with chronic thromboembolic pulmonary hypertensionRiociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.The Soluble Guanylate Cyclase Stimulator IWP-953 Increases Conventional Outflow Facility in Mouse Eyes.Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food.Advances in the management of chronic thromboembolic pulmonary hypertension.Developments in pulmonary arterial hypertension-targeted therapy for chronic thromboembolic pulmonary hypertension.The pathophysiology of pulmonary hypertension in left heart disease.Riociguat for the treatment of pulmonary hypertension.Chronic thromboembolic pulmonary hypertension: detection, medical and surgical treatment approach, and current outcomes.Lung Circulation.Current Approach to the Diagnosis and Management of Portopulmonary Hypertension.Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?Pulmonary hypertension: diagnostic approach and optimal management.Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension.A review of therapeutic agents for the management of pulmonary arterial hypertension.Riociguat for the treatment of pulmonary hypertension: a safety evaluation.Long-term outcomes of surgery for chronic thromboembolic pulmonary hypertension compared with medical therapy at a single Korean center.Clinical implications of riociguat pharmacokinetics and pharmacodynamics: introduction to the riociguat clinical pharmacology supplement.Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.Results from more than 20 years of surgical pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension in Denmark.Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat.Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease.Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?Operative and Functional Outcome After Pulmonary Endarterectomy for Advanced Thromboembolic Pulmonary Hypertension.The anticoagulant effects of warfarin and the bleeding risk associated with its use in patients with chronic thromboembolic pulmonary hypertension at a specialist center in Japan: a retrospective cohort study.
P2860
Q26470534-3A912913-4181-4B08-BD9B-24F02714B376Q26746202-FBD2EFFF-15EC-4561-9A0C-D40DC468A04BQ26748611-D20ACC03-8227-4EF6-B568-E17DC62BB758Q33596457-F56C1C91-A04F-450D-9EF0-BC5042BB1AB5Q35214485-C8D65DB8-BC45-4AF9-801C-007B40421999Q36738013-FBC219F1-3CCF-4AC3-B1B4-17DC00BE2EEDQ36881692-835B9889-D6D1-4548-A95F-E5226084572EQ36881715-C2395682-6DF1-4D4E-B4AE-F1108638E16AQ36881733-53A53F8A-2919-428D-B073-C24BBB502A02Q38560132-8A5075D9-F790-4DD3-9D50-219F09F16C43Q38586326-B595756B-45CF-443E-B900-9CD27283A5FEQ38616615-B38EFC18-9451-4EDD-9E96-B85541D32E13Q38645382-0ADD4B23-1A10-4F0A-BF60-CF6061D38C39Q38688825-527645E4-BC2E-4915-BA5F-55E7D371F096Q38804579-ECA19EEB-2A71-486E-8336-602905640AEEQ38813349-30AF1CF9-26B7-444F-8E53-162959EAAC76Q38818606-D92705A6-A6ED-4436-8B73-6665D1B38D5EQ38818645-CBB31658-5872-4DE3-8109-B57D2E883EA6Q38824298-5FC95D18-5D16-48B9-B35E-CF611896C380Q38826921-223AA8B8-6B3E-449B-8427-37EED598E2D4Q38946618-0B4E8988-6662-4E68-BD29-2AB3922F8E0EQ38983098-7F5172BC-B13B-461C-829C-4DF937639528Q39298766-BC8C8440-26C7-4DD5-AD7A-163E82F7AF8AQ45906325-A1C27385-7A46-4FB4-98D5-8D01F48604EBQ47241943-0B8C2B33-87A6-46A2-AC83-FCB25C72575CQ47287868-5E902071-B3A0-4441-A05E-41A79DF32EABQ47584698-EFEF12AE-D906-4CB9-AF4E-8630F5CEC36DQ47667631-734FD7FB-84E1-4059-87FA-788D67BFF937Q50092007-6C5B81E6-3E57-462F-A14A-7B2AD3591569Q53810463-C78A7F44-D174-4B46-B928-FFC5500A60B4Q55258487-0B5AE683-08DA-4EBF-838D-24A2B2B1CCA7
P2860
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Riociguat for the treatment of ...... erm extension study (CHEST-2).
@ast
Riociguat for the treatment of ...... erm extension study (CHEST-2).
@en
Riociguat for the treatment of ...... n: a long-term extension study
@nl
type
label
Riociguat for the treatment of ...... erm extension study (CHEST-2).
@ast
Riociguat for the treatment of ...... erm extension study (CHEST-2).
@en
Riociguat for the treatment of ...... n: a long-term extension study
@nl
prefLabel
Riociguat for the treatment of ...... erm extension study (CHEST-2).
@ast
Riociguat for the treatment of ...... erm extension study (CHEST-2).
@en
Riociguat for the treatment of ...... n: a long-term extension study
@nl
P2093
P50
P1476
Riociguat for the treatment of ...... erm extension study (CHEST-2).
@en
P2093
Andrea M D'Armini
Arno Fritsch
Eckhard Mayer
Gérald Simonneau
Martin R Wilkins
Neil Davie
Nick H Kim
Pablo Colorado
P304
P356
10.1183/09031936.00087114
P577
2014-11-13T00:00:00Z